Evidence map›Paper›PMID 41895716›Full record

ArticleJournal for immunotherapy of cancer2026

Liver-directed AAV-IL-10 therapy enhances CD8

Chia-I Lin, Yi-Wei Chiu, Meng-Syuan Yen, Yu-Wen Wang, Ying-Hsuan Wu, Ya-Hui Chuang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chia-I LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Yi-Wei ChiuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Meng-Syuan YenDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Yu-Wen WangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Ying-Hsuan WuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Ya-Hui ChuangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan yahuichuang@ntu.edu.tw.ORCID http://orcid.org/0000-0003-0857-0035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe liver's inherently immunosuppressive microenvironment presents a major barrier to effective immunotherapy for hepatocellular carcinoma (HCC). Although interleukin-10 (IL-10) has demonstrated antitumor activity in several cancer models, its therapeutic potential in HCC remains unclear. Here, we investigated whether liver-directed delivery of IL-10 using an adeno-associated virus vector (AAV-IL-10) could enhance antitumor immunity in HCC.

methodsSyngeneic orthotopic and intrahepatic metastatic HCC mouse models were used to evaluate the effects of liver-directed AAV-IL-10 therapy. Tumor burden, immune cell infiltration, and functional activation were assessed by flow cytometry and related analyses.

resultsLiver-directed AAV-IL-10 treatment significantly reduced intrahepatic tumor burden and promoted robust infiltration of CD8

conclusionsLiver-directed AAV-IL-10 delivery overcomes local immunosuppression and enhances CD8

Indexed as

Carcinoma, HepatocellularCD8-Positive T-LymphocytesDependovirusGenetic TherapyInterleukin-10Liver NeoplasmsAnimalsCell Line, TumorGenetic VectorsHumansImmunity, CellularImmunotherapyMiceMice, Inbred C57BLTumor MicroenvironmentInterleukin-10CytokineGene therapyHepatocellular CarcinomaImmunotherapyT cell

Identifiers

PMID41895716
PMCPMC13034371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.